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Zusammenfassung
Obwohl humanes Nabelschnurblut als Quelle von Stammzellen für ex-
perimentelle Therapien von Erkrankungen des Zentralnervensystems
derzeit intensiv untersucht wird, ist noch wenig über die zellulären
Prozesse bekannt, die der funktionellen Verbesserung von Ausfaller-
scheinungenzugrundeliegen.IndervorliegendenStudieuntersuchten
wir das Potenzial humaner Nabelschnurblutzellen, funktionelle Verbes-
serungen nach einem experimentellen Schlaganfall zu unterstützen.
Die Experimente wurden mit spontan hypertensiven (SH) Ratten
durchgeführt,derenmetabolischeGrunderkrankungendemRisikoprofil
menschlicher Schlaganfallpatienten entsprechen.
NachdreiWochenderKonditionierungfürdieVerhaltenstestsRotaRod
undBeamwalkwurdeeinexperimentellerSchlaganfalldurchpermanen-
teOkklusiondermittlerenHirnarterie(middlecerebralarteryocclusion,
MCAO) ausgelöst. Im Zuge der Zelltherapie wurden 1x10
6 kryokonser-
vierte CD34
+- oder CD34
--Zellen 8 bis 10 Stunden nach Verschluss der
rechten mittleren Hirnarterie intravenös appliziert. Die Verhaltenstests
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score (mNSS) bis 29 Tage nach Eintritt des experimentellen Schlagan-
falls durchgeführt, um die Entwicklung neurofunktionaler Defizite im
Verlauf beurteilen und quantifizieren zu können. Dabei wurde eine an-
nähernd komplette Rückbildung von Ausfallerscheinungen bei Gabe
beiderZellpopulationenbeobachtet.UmtransplantierteZellenlokalisie-
renzukönnen,wurdendiesemitdemFluoreszenzfarbstoffCFSEunmit-
telbar vor der systemischen Zellgabe markiert. Sowohl nach der Gabe
vonCD34
+-alsauchCD34
--ZellenkonntenCFSE-markierteZelleninder
Grenzzone zwischen zentraler Kolliquationsnekrose und funktionellem
Hirngewebe detektiert werden. Immunhistologische Untersuchungen
mitanti-CD68AntikörperngegenneuronaleMarker(NF-L,Chromogranin)
zeigten eine verstärkte Ansammlung von Zellen monozytärer Natur,
währendneuronaleZellenhumanenUrsprungsnichtidentifiziertwerden
konnten.
Schlüsselwörter: Verhaltenstest, Okklusion der mittleren Hirnarterie,
Stammzelle, Schlaganfall, Transplantation
Introduction
Cell transplantation after stroke has been used to either
substitute stem cells for neuronal differentiation or to
promote the endogenous regenerative potential and
plasticity of the brain with the therapeutic goal being
restoration of functional neuronal networks. However,
the use of embryonic or fetal grafts in humans is restrict-
ed by ethical considerations, severe logistical problems,
andbecauseintracerebraladministrationofhomologous
embryonic stem cells may lead to teratocarcinomas as
demonstratedinrodents[11].Therefore,alternativestem
cell sources for treatment of neurological disorders have
been evaluated in rat models, among them human bone
marrow[7]andhumanumbilicalcordblood(HUCB,[23]).
HUCB mononuclear cells are easy to obtain and show
extensive proliferative capacity in vitro [34]. Similar to
the percentage observed in bone marrow, 1%-2% of
mononuclear HUCB cells express CD34, the surface
markermoleculeofhemopoieticstemcells[2].Sanchez-
Ramos et al. [26] and Bicknese et al. [3] demonstrated,
that HUCB-derived cells express neuronal markers when
cultivated in media known to promote expansion and
differentiation of neuronal precursors. Consequently,
HUCB cells were used for treatment of experimental
neurological diseases in animal models like traumatic
brain injury [22], paraplegia caused by spinal cord injury
[27], amyotrophic lateral sclerosis [14], and stroke [6].
The therapeutic benefit in stroke treatment was demon-
strated by intravenous administration of HUCB cells en-
riched for CD34
+ cells after middle cerebral artery occlu-
sion (MCAO) in Wistar rats [6].
However, because of the heterogeneity of HUCB mono-
nuclearcells,itisthequestionwhetherornottheclassic-
al hemopoietic stem cell characterized by the surface
marker CD34 (as used in the study of Chen et al. [6]) is
responsible for the therapeutic benefit. To evaluate
whether CD34 is an appropriate marker to describe the
cell population responsible for the therapeutic benefit
upon experimental stroke in rats, we prepared by separ-
ation with magnetic beads highly enriched CD34
+ cells
and used them in rat MCAO in comparison to cell prepar-
ations which were depleted from CD34
+ cells. RotaRod,
Beamwalk, and mNSS, a modified neurological score
system[6],wereusedtoevaluatefrequentlytheneuromo-
toriccapabilityoftheanimals.Inordertolocalizethecells
in tissue sections the cells were labeled prior to injection
intracellularly with the fluorescence dye carboxyfluores-
cein succinimidyl ester (CFSE) according to Parish [24].
When our experiments were started by establishing the
MCAO model we found the dimension of functional defi-
cits in Wistar rats not very suitable for the evaluation of
subtledistinctionsintheefficiencyoftreatmentprotocols.
Therefore, further experiments were performed with
spontaneouslyhypertensive(SH)rats.Duringmaturation
these animals develop an idiopathic hypertension,
hyperinsulinemia, hypertriglyceridemia and hypercholes-
terinemia associated with reduced cerebral blood flow
[28] very similar to the risk profile of stroke patients. Le-
sions are larger and more consistent as with normotens-
iverats[10],[31].Permanentinsteadoftransientsurgical
occlusion was performed in our MCAO model since the
majority of stroke events in humans (85%) is caused by
thrombembolism[8].Anotherimportantparameteristhe
time window selected for therapy. We performed cell in-
jection 8-10 hours after experimental MCAO which is
earlierthaninotherstudies[6],[33]inordertointervene
in the early remodelling phase following the ischemic in-
sult.
In this study, we could demonstrate a nearly complete
recovery from functional deficits caused by permanent
MCAOinspontaneouslyhypertensiveratsbyintravenously
administered HUCB cells. Furthermore, human CD34
-
cells from HUCB were as sufficient for successful treat-
ment of stroke in SH rats than CD34
+ cells. Both cell
populations were found accumulated in the border zone
of the lesion. CD34
- cells comprise more than 98% of
HUCB cells.They are much easier to obtain than purified
CD34
+ cells and may provide an important source for
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Materials and methods
Human cord blood (HUCB) sources
Samples of HUCB were obtained from several hospitals
in Leipzig, Germany. They were taken in accordance to
ethicalprescriptsimmediatelyafterdelivery.Mononuclear
cells were isolated as described below and stored in the
gaseousphaseofliquidnitrogen.Cryopreservedsamples
of cord blood were obtained from the cord blood bank
VITA34 Inc., and the cells were separated after thawing
the frozen HUCB samples.
HUCB cell preparation
The mononuclear cell fraction of pooled cord blood
samples was separated using Ficoll-Paque PLUS (Amer-
sham Biosciences, Uppsala, Sweden) density gradient
centrifugation according to the manufacturers protocol.
Cells were stored by freezing after addition of 5.5% di-
methyl sulfoxide (DMSO, Serumwerke Bernburg Inc.,
Bernburg,Germany)insmalldropsaccordingtostandard
operation procedures using a computer-controlled freez-
ing device (Sylab, Austria). Prior to transplantation, cryo-
preserved HUCB cell samples were thawed rapidly in a
water bath at 37°C, transferred to a tube containing a
mixture of 10 ml RPMI 1640 Medium (Biochrom Inc.,
Berlin, Germany), 2 ml DNAse I and 60 µl 0.5M MgCl2
(Sigma, Germany) at 37°C. Cells were centrifuged at
1250 rpm for 5 minutes at room temperature, the super-
natant was removed and the pellet resuspended in 8 ml
phosphate buffered saline (PBS, pH 7.4; Biochrom Inc.)
and 2 ml DNAse I for a second washing step. Cell viability
was then assessed by dye exclusion using a 0.4% Trypan
BluesolutionandaNeubauercountingchamberinorder
to adjust the cell number in the samples to viable cells.
Only samples with a viability above 90% were used for
furtherprocessing.Thereafter,cellswerecentrifugedand
resuspendedinafinalvolumeof300µlPBSper10
8total
cells.
Enrichment or depletion of CD34
+ cells
TheenrichmentordepletionofCD34
+cellswasperformed
usingmicrobead-conjugatedanti-CD34antibodies(CD34
Progenitor Cell Isolation Kit), LS
+/VS
+ columns and a Su-
perMACS magnetic cell separator (all Miltenyi-Biotech
Inc.,BergischGladbach,Germany)accordingtomanufac-
turers instructions. Briefly, 100 µl of FcR blocking was
added per 10
8 cells to inhibit unspecific Fc receptor-me-
diatedbinding.Sampleswereincubatedwithmicrobead-
conjugatedanti-CD34antibodysolution(cloneQBEnd/10
against epitope II) for 30 minutes at 6°C. Cells were se-
lectedusingaLS
+/VS
+columnandaSuperMACSmagnet-
ic cell separator. CD34
- cells remaining in the column
were washed out and collected in a separate tube. A
representative fraction of separated cells was incubated
with a conjugated non-competing anti-CD34 antibody
(dilution 1:100, Immunotech, clone 581 against CD34
epitope III) for further FACS analysis.
Sample analyses
In order to characterize the cell samples, flow cytometric
analyses were performed using a FacsCalibur™ Scanner
equipped with the CellQuest™ software (both Becton-
Dickinson, Franklin Lakes, USA). Integral cells were de-
termined above the level of 200 arbitrary units on the
sideward scatter scale (FSC-H). Events below this level
were regarded as cell fragments according to control ex-
periments.
Cell labeling with carboxy
fluoresceindiacetate succinimidyl ester
(CFSE)
For localization in histological sections, HUCB cells were
labeledinvitrobeforeinjectionwith0.1%CFSE(Molecular
Probes Inc., Eugene, USA) for 10 minutes in RPMI 1640
medium at 37°C. Labeling efficiency was verified by
cytofluorometricanalysisandthesampleswereonlytaken
for further experiments when at least 99% of the cells
showed an increase in fluorescence intensity at least by
a factor of 100. Cell viability was again calculated by the
Trypan Blue method and a total amount of 1x10
6 viable
CD34
+ or CD34
- cells was injected i.v. per animal. The
distribution of CFSE-labeled cells was examined by UV
microscopy in tissue sections as described below.
Animals
All experimental procedures were approved by the Exper-
imental Animal Committee of the Regional Council of
Leipzig. 48 male spontaneously hypertensive (SH) rats
(Charles River Laboratories), weighting 220 g to 275 g
were used in the experiments. Animals were maintained
in individual home boxes at 12:12 hour light:dark cycle.
Light was turned on at 6:00 a.m. Rats were allowed to
have access to food and water ad libitum and were kept
atroomtemperature(23°C).Conditioningofanimalswas
started at least 7 days after animal delivery to allow for
adaption to the new environment.
HUCB cell injection
8 to 10 hours after MCAO-induced brain ischaemia, the
animalsreceivedeitherHUCBcellsassinglecellsuspen-
sion or phospate buffered (pH 7.4) physiological saline
(PBS) for control. Animals were shortly anaesthetized
using a Plexiglas chamber flooded with CO2 and were
rapidly transferred to an application desk on which the
tail was fixed. A total amount of 1x10
6 viable CD34
+ or
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- cells in 1 ml total fluid volume (PBS) were injected
into a tail vein.
Permanent middle cerebral artery
occlusion (MCAO)
Rats were initially anaesthetized with ketamine chloride
100 mg/kg body weight (Merial Ltd., Hallbergmoos, Ger-
many), 10 mg/kg xylazine (Bayer Inc., Leverkusen, Ger-
many) and 0.1 mg/kg atropine (Ratiopharm Inc., Ulm,
Germany), delivered intraperitoneally. Then, the animals
were kept in their home cages until the corneal reflex
could not be triggered anymore as a sign of deep anaes-
thesia. The head of the animal was then fixed on a tooth
bar mounted in a flexible face mask allowing oxygen
supply throughout the surgical procedure. The mask can
be rotated up to 30 degrees around the longitudinal axis
to turn the animal´s head to get better access to the
middle cerebral artery (MCA). Animals were placed
throughout the whole surgical procedure on a feedback
controlled warming pad (Fine Science Tools Inc., Heidel-
berg, Germany) which included measurement of pulse
rate and blood oxygenation status (Nonin Medical Inc.,
Plymouth, USA). Both eyes were protected against drying
with sterile eye ointment.
The MCA was occluded according to a method reported
by Tamura [30]. A L-shaped incision was performed in
the scalp and the musculus temporalis between eye and
ear on the right side. Then, the head of the animal was
turned to the left for easy access to MCA proximally to its
origin at the circulus arteriosus. The zygomatic arch was
carefully removed using a bone forceps. A subtemporal
craniotomy was carried out using a dental drill and the
dura mater was locally incised with a fine needle. Then
the MCA was carefully elevated from brain surface by a
hook mounted on a stereotactic frame. For permanent
vesselblockinganelectricallyheatedwireloopwasused
todisruptandimmediatelyoccludetheMCA.Theincisions
were sutured using absorbable 4-0 surgical threads and
the wound surface was temporally anaesthetized by
lidocaine gel (2%, Farcopharma Ltd, Cologne, Germany).
Followingsurgery,animalsweretakenbacktotheirhome
cages to recover. Postsurgical anaesthesia was provided
by adding metamizole-Na (25 mg, Ratiopharm Inc., Ulm,
Germany) and 5% glucose to the water storage can (40
ml) of each cage daily for one week.
Functional behavioral testing
All animals received a 3-week training on a set of behavi-
oral tests before MCAO. The battery of functional tests
comprisedthecomputercontrolledRotaRodsystem(TSE
Systems Ltd., Bad Homburg, Germany), the beam walk
test and the modified neurological severity score (mNSS,
[6]).
The Rota Rod test was basically performed according to
Dunham and Miya [9] and Jones and Roberts [17]. Rats
were placed on a motor driven horizontal cylinder (the
rod) in up to four individual chambers of the device. The
time animals are able to remain on the accelerating cy-
linder was measured. The acceleration, final rotation
speed and time of animal drop off were controlled and
documented digitally. In our setting, rotation speed in-
creased from 3 rpm to 60 rpm within 3 minutes. A trial
was terminated if an animal fell or jumped off the rod or
if the rat remained on the rod for 200 seconds. Animals
were allowed to recover in their home cages for at least
3 minutes before a new trial was started. Mean duration
(in seconds) was recorded from five individual trials.
In the beam walk test according to Hamm et al. [15], rats
mustmoveoverahorizontallymountedbar(1minlength,
14 mm in diameter) to enter their home boxes placed at
the end of the beam. The time animals took to get over
the bar was measured in five trials and the mean time
was recorded. If the rat slipped of the beam and hung, a
maximum time of 20 seconds was noted for this trial. If
an animal fell off the bar, it received a 30-second malus.
Table 1 shows the items for the modified neurological
severityscore(mNSS)accordingtoChenetal.[6].Neuro-
logical function including motoric and sensoric systems
as well as reflexes and a balance test is graded on a nu-
meric scale from 0 to 18 (0 for no disorders/normal
functionandamaximumlesionscoreof18).Ifananimal
was unable to perform a test or if the lack of a tested re-
flex was noticed, a score point was given. Thus, the
higher the score the more severe the ischemic lesion
causedbyMCAO.1-6mNSSscorepointswereconsidered
as mild, 7-12 score points as medium and 13-18 score
points as severe injury.
A baseline measurement was taken one day prior to
surgery. From the day following the surgical procedure,
RotaRod and beam walk testing were performed daily up
to 7 days post operation. Thereafter, tests were carried
outeveryseconddayuntilday29.Allanimalsunderwent
the mNSS test at day 1, 4, 7, 11, 15, 19, 23, and 27.
Behavioral testing was conducted during the light phase
and animals were not removed from their familiar envir-
onment. All experiments were done by one researcher
blinded to the experimental groups, and the sequence of
tests was randomised between the animals each day.
Data are presented as absolute values in seconds
(RotaRod and beam walk) or score points (mNSS).
Tissue preparation,
immunohistochemistryandhistological
analysis
Afterterminationofbehavioraltestsanimalsweredeeply
anaesthetizedwithCO2andwereperfusedtranscardially
with physiological saline solution. The brains were re-
moved immediately and evaluated for gross macroscop-
icalpathology.2mmthickfrontalslicesoffreshratbrains
werecutandthensnapfrozenondryiceusingprecooled
metal plates with polished surfaces. 10-15 µm thick
serial sections throughout the whole brain were fixed in
8% ethanol 1/1 v:v for 15-30 minutes and then stained
with either Hematoxylin/Eosin (HE) or Giemsa stain
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The beam walk is commonly used to evaluate sensomotoric deficits in rats following MCAO.
(Merck, Haar, Germany), dehydrated and mounted in
Eukitt (Merck). Sections designated for fluorescence mi-
croscopyweremountedinnon-fixedconditioninaqueous
medium (Aquamount; Polysciences, Warrington, USA).
MicroscopywasdoneusingaZeissAxioplan2microscope
withNeofluarobjectivesandtheZeissFluorescencefilter
sets 02, 05, 06, 09, 15 and 26.
After morphologic differentiation between functional tis-
sueversuscolliquationnecrosisortheborderzoneinHE-
stained slices, borderlines between those areas were
marked digitally. Then analysis of the following, corres-
pondingfluorescencesliceswasperformedaftertransfer
of digital borderlines to the fluorescence image.
For further characterization, brain slices were incubated
with mouse monoclonal antibodies against anti-human
CD34, anti-human CD68, anti-human neurofilament-L
fragment(NF-L,70kDa)antibodies,anti-humanchromo-
granin (all Dako Cytomation, Glostrup, Denmark) or anti-
rat CD68 (Dako, Glostrup, Denmark) according to manu-
facturers instructions.
Statistical analysis
All behavioral tests were evaluated for normality and
equalvariances.Analysesofsignificancewereperformed
usingthenon-parametricMann-Whitneytestforcompari-
son of the groups. We also tested the balance of the
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anypotentialimbalancesintheanalysisofthetreatment
effect. Both, differences between treated groups and
control animals as well as differences between CD34
+
and CD34
- treated subjects were evaluated for each be-
havioral test. P-values of 0.05 or less were considered
statistically significant. All data are shown as mean ±
standard deviation (SD).
Results
CharacterizationofseparatedHUCBcells
HUCB mononuclear cells were separated by anti-CD34
antibodies and magnetic beads as described above. Fig-
ure1showscharacterizationofthecellpreparationsused
for treatment studies. The right panel shows the CD34
+
cell enriched population containing a mean proportion
of98.9%CD34
+cellswithaviabilityof>91%(5independ-
ent experiments). The enrichment factor amounted to
more than 50 (mean of 1.8% CD34
+ cells in regular
HUCB). The left panel shows the preparation depleted
from CD34
+ cells. The degree of depletion ranged from
3x to 6x i.e. from 0.1 to 0.5% CD34
+ cells, as determined
in five independent experiments. Viability was >92% in
each experiment.
Figure 1: FACS analysis of HUCB cells used for treatment. Left
panel shows a CD34
+ cell depleted sample stained with an
anti-CD34 antibody (0.4% CD34
+ cells) directed to a non-
competing CD34 epitope as compared to the antibody used
for cell separation. Right panel shows a CD34
+ cell enriched
fraction (98.9%).
Neurofunctional recovery after cell
therapy
Animals were randomly assigned to one of three groups.
Group1(n=18)receivedCD34
+cellswhilegroup2(n=12)
was injected with CD34
-cells. Group 3 (n=18) was taken
as a control receiving a sham injection of PBS.
Rats receiving HUCB cells of both populations showed a
remarkablereductionoffunctionalandneurologicaldefi-
cits in each test with complete remission in the RotaRod
and beam walk test as compared to baseline measure-
ment (Figure 2A-D). Statistically significant differences
(P<0.05) between animals treated with CD34
+cells and
untreateted controls were first observed at day 2 in the
RotaRod (P<0.05, Figure 2A), at day 3 in the beam walk
array (P<0.01, Figure 2B and Figure 2C) and at day 4 in
the mNSS (P<0.05, Figure 2D). CD34
- HUCB cell admin-
istration became superior to saline injection at the third
day in the RotaRod experiment (P<0.05) and the beam
walk test (P<0.01) and at day 4 in the mNSS (P<0.05).
With each functional test a high level of statistical signi-
ficance (P<0.00001) was reached in the plateau phase
of functional recovery (see Figure 2). This level of highly
significant difference was maintained at least from day
11 until the end of behavioural testing.
Comparing CD34
+ HUCB cells with CD34
- HUCB cells, no
statisticallysignificantdifference(P<0.05)wasobserved
with regard to the beneficial effect of both populations
(Figure 2A-D). In the RotaRod test, marginal differences
were only observed at day 9 (P=0.03), day 11 (P=0.04)
and day 29 (P=0.04). Beam walk data were marginally
different only at day 6 (P=0.01) while in the mNSS test
amarginaldivergencecouldbenoticedatday1(P=0.02).
Inallcases,dataobtainedfromanimalsthatwereadmin-
isteredCD34
-HUCBcellstendedtoaslightlylesseffective
treatment as compared to the use of CD34
+ HUCB cells.
However,thenullhypothesis,i.e.nostatisticaldifference
between CD34
+ versus CD34
- HUCB cells, had to be ac-
cepted (P>0.4) in each case.
An example of the sensomotoric performance of experi-
mentalanimals14daysafterMCAOwithandwithoutcell
transplantation as well as before MCAO is given in the
video file attached. A cell-transplanted animal is able to
pass the beam walk within 1.5 to 3.0 s like the healthy
control animal without major stop overs or imbalances,
while a non-transplanted MCAO subject clearly suffers
from sensomotoric disabilities interrupting its walking
frequently with the tendency to loose balance and to fall
down.
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6 cells enriched or depleted
from CD34
+ cells by magnetic bead separation (n=18 for CD34
+ cell treatment; n=12 for CD34
- cell treatment) or 1 ml of PBS
for control (n=18) 8 to 10 hours following ischemia. Behavioral tests (RotaRod, A; beam walk, B and C) and the modified
neurological severity score (D) were performed during the phase of conditioning, before (Base line) and after MCAO throughout
the evaluation phase. CD34
+ and CD34
- treated animals showed statistically significant improvement of neurological deficits
in the plateau phase starting at day 11 (P<0.0001 in all test arrays). For statistical details in the early phase (D2-D9) see
description in the text. Data are presented as absolute values ± SD.
HistologicallocalizationofHUCBcellsin
brain and other organs
For histological studies the cells were labeled with CFSE
prior to injection as described above and serial tissue
sections were prepared after termination of the animal
experiments at day 29 after MCAO for investigation by
UV microscopy. Control experiments were performed
without using HUCB cells as shown in Figure 3 for HE-
staining (Figure 3A) and the green fluorescence channel
(Figure 3B) displayed in parallel sections, while CFSE-
labeled HUCB mononuclear cells were used in the exper-
iment shown in Figure 3C in the green channel versus
theredchannel(Figure3D)inordertodemonstateexclu-
sion of autofluorescence. CFSE-labeled cells could be
detectedclearly(Figure3E-H)uponintravenousadminis-
trationofbothpreparations,CD34
+andCD34
-HUCBcells.
Theywerefoundaccumulatingintheborderzone(Figure
3F and H), while no fluorescent cells were observed at
the contralateral side of lesion or in control animals (Fig-
ure 3B).
However, we were not able to identify neuronal cells of
human origin by staining with antibodies against human
NF-L or chromogranin as assessed four weeks after cell
injection.Stainingwithanti-ratCD68showedamoderate
anddiffuseactivityofhostmicroglialcellsandmonocytes
in ischemic areas (Figure 4A and D). In both groups, an-
imals transplanted with either human CD34
+ or CD34
-
cells, an increase of human CD68
+ cells could be found
in the border zone of the lesion (Figure 4B and D), while
human CD68 could not be found in the contralateral
hemisphereorinanimalsthatwerenottransplantedwith
human cells (Figure 4C and D). Staining with anti-human
CD34 antibodies suffered from diffuse fluorescence
activity in most endothelial cells. After HUCB cell admin-
istration, no tumor formation was found in any animal
until termination of the experiment at day 29 post opera-
tion.
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+ and CD34
- HUCB cells in serial sections of SH in rat brains 29 days after MCAO. A:
controlanimalwithoutcelltherapy,HEstaining;B:controlanimal,UVmicroscopywithgreenfluorescence;C:HUCBmononuclear
cell treatment, green fluorescence, the borderline between the necrotic central area and the border zone to unaffected tissue
is marked according to HE serial section; D: HUCB mononuclear cell treatment, red fluorescence; E: CD34
+ HUCB cell treatment,
HE staining; F: CD34
+ HUCB cell treatment, green fluorescence (inverse colours); G: CD34
- HUCB cell treatment, phase contrast
microscopy; H: CD34
- HUCB cell treatment, green fluorescence. 400fold magnification in all images.
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+/CD34
- cell
transplantation. Moderate and diffuse fluorescence signals from cells positive for rat CD68 occurs in the lesioned hemisphere
of transplanted and control animals (A). A strong increase of fluorescence caused by cells positive for human CD68 cells could
be detected in animals transplanted with both, CD34
+ and CD34
- cells indicating a "monocyte fate" of administered cells (B).
Cells positive for human CD68 could not be detected in control rats (C) or in the contralateral hemisphere. D shows the level
of fluorescence according to a score point system (0=none, 1=low, 2=moderate, 3=high fluorescence activity).
Tissue samples from heart, kidney, spleen and bone
marrowofexperimentalanimalswereexaminedforCFSE-
positive cells. Only few CFSE-positive cells were found in
spleen and bone marrow of animals transplanted with
CD34
+ cells (Table 2).
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brackets. + = high density of CFSE-positive cells; +/- = only few CFSE-positive cells were detected; - = no CFSE-positive cells
were detected in slices of harvested organs.
Discussion
The experimental model
In order to verify the benefit of new therapeutical proced-
ures for future use in humans, it is important to design
experimental animal models in close relation to clinical
requirements. In many human patients suffering from
stroke, the capillary system is damaged by long-term hy-
pertension, hypertriglyceridemia and hypercholester-
inemia. Therefore, we performed the experiments in SH
rats instead of strains like Wistar or Sprague Dawley
which were used in previous studies [6], [33]. According
to Traystman [31], SH rats suffer from larger and more
consistent ischemic lesions and showed less variable
functional deficits within the experimental groups which
couldbeconfirmedbyownexperiences(datanotshown).
Close relation to clinical reality for potential treatment
protocols was also the reason to adopt the permanent
artery occlusion instead of transient blood vessel block-
age by a surgical filament [20]. The time frame for cell
therapy (8-10 hours after MCAO) would be feasible in the
clincalpracticeofastrokeunitconsideringeventhemost
unfortunate delay until the patients had arrived and
passed all diagnostic procedures.
In principle, the use of xenogeneic (human) cells might
induce a local immune response in the (rat) host which
could hypothetically interfere with treatment e.g. by re-
leasing neurotropic cytokines. However, Chen et al. [6]
could demonstrate functional recovery by using HUCB
cells in rat MCAO without immunosuppression. Their ex-
perimental design and results were comparable to the
study of Willing et al. [33] using cyclosporine A. Since
neuroprotective effects have been described recently by
immunosuppressive drugs [18] we decided to omit their
use. Moreover, recent control experiments (data not
shown) with an irradiated human T cell clone with irrele-
vantspecifityinsteadofHUCBcellsshowednotherapeut-
ic effect at all. Because of irradiation at 5 Gy, T cells were
not able to divide but remained viable in parallel in vitro
culture for 29 days and were still able to produce TNF-α.
Bythisexperiment,wewantedtoshowthataxenogeneic
immunereactionofthehosttowardscellsofhumanorigin
was not responsible for the success of treatment.
Functional improvement in behavioral
tests by CD34
- cells
In this study, cell therapy with HUCB-derived cells
demonstratedasignificantimprovementofneuromotoric
functioninSHratsbutCD34
-cellswerenearlyaseffective
as CD34
+ cells. The number of remaining CD34
+ cells in
the depleted preparation was below 0.5% i.e. less than
5000 cells, while the enriched preparation contained
nearly 1 million viable CD34
+ cells. If CD34
+ cells would
be the cellular entity responsible for the therapeutic be-
nefit there should be a clear distinction between both
preparations in their functional potential.
Veryrecently,Taguchietal.[29]havereportedthatHUCB-
derived CD34
- cells in contrast to CD34
+ cells were not
able to promote angiogenesis in SCID mice upon experi-
mentalfocalcerebralischemia.However,theircellswere
administeredmuchlateri.e.after24hoursandpersistent
focalmotordeficitswerenotobservedintheirmodel.Our
results indicate that other cells than CD34
+ cells seem
to be involved. Interestingly, a cell population isolated
from adult human brain and characterized as CD133
+,
CD34
- and CD45
- could expand and differentiate effect-
ivelywithinthebrainofneonatallyimmunodeficientmice
[32]. Despite that the cells in the study of Uchida et al.
[32]weredescribedascentralnervoussystemstemcells,
itisapossibilitythatmoreimmaturestemcells,described
by another denominator, such as CD133, were respons-
ible for the therapeutic benefit. Gallacher et al. [13]
demonstrated that CD133
+, CD34
- cord blood cells are
capable of forming heamtopoietic cells in vitro as well as
in NOD/SCID mice and these immature cells may be re-
sponsible for the therapeutic effect seen in our CD34
-
cells.
The number of 10
6 cells injected systemically is relatively
small as compared to the mass of ischemic tissue. Signi-
ficant functional recovery could be detected at least at
day4inthemNSStest,whilethemaximumimprovement
of neuromotoric functions was reached at day 11 and
was maintained until the end of study. It seems to be
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develops appropriate neuronal connections, restores
functional cerebral networks and leads to a conspicuous
behavioural improvement within such a relatively short
period of time. However, these cells may initiate or accel-
erate endogenous regeneration processes.
In general, an ischemic cerebral lesion consists of a
centralcolliquationnecrosissurroundedbythepenumbra,
an area of incomplete i.e. reversible cell damage [21].
The penumbra, as the “tissue at risk”, is a border zone
dividingtheregionsoftotalischemiccelldestructionfrom
those containing unaffected and functional tissue. This
area is the main therapeutic target for treating stroke by
regeneration and cellular restoration [12].
Upon intravenous administration, CFSE-labeled cells ac-
cumulated in a border zone comprising the brain area
remaining from the penumbra after 4 weeks. Moreover,
we found HUCB cells in the ipsilateral hemisphere of le-
sionandonlyveryfewCFSE-labeledHUCBinthecontralat-
eral ones as shown first by Chen et al. [6]. We were not
able to detect cells of human origin expressing neuronal
markersindicatingthatneurofunctionalrestorationisnot
related to neurogenesis from the transplanted cells. The
detectionofcellsbeingpositiveforhumanCD68,acellu-
lar marker for monocytes and macrophages, demon-
strated that human cells take part in local processes of
organisation of the lesion and the surrounding tissue.
Findings of Borlongan et al. [5] indicate that trophic
and/orneuroprotectivefactorsproducedbytransplanted
cells are mere important for neurofunctional restoration
than the generation of new neurons.
Here, we could demonstrate that this accumulation was
not selective for CD34
+. The accumulation indicates
chemotactic attraction of transplanted cells towards the
lesionortopicexpressionofadhesionmoleculeswiththe
same result: focal accumulation of migrating cells close
to the ischemic lesion. Ischemic brain tissue expresses
chemotactic proteins like MCP-1 [19] and microvascular
endothelial cells significantly upregulate the expression
of ICAM 1, vascular adhesion molecule-1 (VCAM) and E-
selectinfollowingacuteischemiccerebralinjuryasrepor-
tedbyZhangetal.[35]andBlannetal.[4].Itisimportant
to note that the blood brain barrier becomes leaky from
3 hours to 4 days after stroke in rats [16], [1], [25] which
may allow for unselected entry of migrating cells. How-
ever, more work has to be done to investigate the mech-
anisms of cell migration and recruitment of regenerative
potential in detail.
Inconclusion,wecoulddemonstratethatCD34
+depleted
HUCB cells accumulate in the border zone of the
ischemic lesion and are highly sufficient for successful
treatmentofanischemicinsultafterpermanentocclusion
of the middle cerebral artery in SH rats showing a risk
profile. This population of cells is much easier to obtain
than purified CD34
+ cells which are a rare fraction in
HUCB. Because HUCB cells are widely available, easy to
store and to handle, they may provide an important
source for treatment of stroke in future cell based ther-
apies.
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Example of the sensomotoric performance of
experimental animals 14 days after MCAO with and
withoutcelltransplantationaswellasbeforeMCAO:
A cell-transplanted animal is able to pass the beam
walk within 1.5 to 3.0 s like the healthy control
animal without major stop overs or imbalances,
while a non-transplanted MCAO subject clearly
suffers from sensomotoric disabilities interrupting
its walking frequently with the tendency to lose
balance and to fall down.
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